

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope  
addressed to: Commissioner for Patents, Box Patent Application,  
Washington, D.C. 20231 on February 20, 2002.  
By: Nancy Ramos  
Printed: Nancy Ramos

J1017 U.S. PTO  
10/079111  
02/20/02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Susan G. Stuart and David G. Streeter

Title: BREAST CANCER MARKER

Serial No.: To Be Assigned

Filing Date:

Herewith

Examiner: To Be Assigned

Group Art Unit:

To Be Assigned

---

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual

of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**. **A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.



David G. Streeter, Ph.D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

Date: February 29, 2002

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office				Atty Docket No.		Serial No.	
				PC-0053 CIP		To Be Assigned	
LIST OF REFERENCES CITED BY APPLICANTS				Applicant(s)			
(Use several sheets if necessary)				Stuart et al.			
				Filing Date		Group	
				Herewith		To Be Assigned	
U.S. Patent Documents							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
Foreign Patent Documents							
						Translation	
		Document	Date	Country	Class	Subclass	Yes No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	1	Gish, K., "Breast Cancer. Surveying half the human genome with transcription profiling for better diagnosis prognosis, and therapy", AWIS Mag., 28 (3):7-10					
	2	Perou C.M., et al., "Molecular portraits of human breast tumours", Nature (17 August 2000) 406: 747-752					
	3	Khazaie et al., "EGF receptor in neoplasia and metastasis", Cancer and Metastasis (1993) 12: 255-274					
	4	Zhou Z., et al., "UP-Regulation of Human Secreted Frizzled Homolog in Apoptosis and Its Down-Regulation in Breast Tumors", Int J. Cancer (1998) 78:95-99					
	5	Chen, L., et al., "Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization", Oncogene (1990) 5: 1391-1395					
	6	Ulrix W., The differentiation-related gene 1, drgl, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells", et al., FEBS Lett (1999) 455:23-26					
	7	Sagar, R. et al., "Maspin: A Tumor Suppressing Serpin", Curr Top Microbiol Immunol (1996) 213:51-64					
	8	Lee S.W. et al., "Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment", Proc Natl Acad Sci USA (March 1992) 89:2504-2508					
	9	Grodin, et al., "Response of colon cancer cell lines to the introduction of APC, a colon-specific tumor suppressor gene", Cancer Research (1995 April 1); 55 (7) 1531-9					
	10	Ota, T. et al., (Direct Submission), GenBank Sequence Database (Accession CAC39756), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894, (GI: 14272636)					
	11	Winkelmann, J.C. et al., (Direct Submission), GenBank Sequence Database (Accession AAD49220), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894, (GI: 10800122)					
	12	Banerji, et al., (Direct Submission), GenBank Sequence Database (Accession AAD42764), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894, (GI: 5359673)					
	13	Banerji, et al., "LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan", The Journal of Cell Biology, (February 22, 1999) 144(4):789-801					
Examiner				Date Considered			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.</p>							

10/07/99  
U.S. PTO

10/07/99  
U.S. PTO

02/20/02